ACS抗凝进展专题知识.pptVIP

LMWH与UFH相比,提升风险收益比Mismettietal.BrJSurg2023;88:913–30.Meta-analysisof

datafrom48,624patientsincludedin51studiesLMWHbetterUFHbetter AsymptomaticDVT RR=0.90(0.79-1.02)

n=17,995 p=0.10 ClinicalPE RR=0.88(0.64-1.20)

n=46,646 p=0.41 Clinicalthromboembolism RR=0.71(0.51-0.99)

n=13,776 p=0.049 Death RR=1.04(0.89-1.20)

n=41,387 p=0.63 Majorhaemorrhage RR=0.89(0.75-1.05)

n=18.555 p=0.16 Totalhaemorrhage RR=0.92(0.79-1.07)

n=19,315 p=0.27 Woundhaematoma RR=0.89(0.74-1.07)

n=16,087 p=0.21 Transfusion RR=1.03(0.94-1.12)

n=12,777 p=0.543.02.52.